Prognostic Value of Thyroglobulin Serum Levels and 131I Whole-Body Scan after Initial Treatment of Low-Risk Differentiated Thyroid Cancer

Thyroid

Volumn 14, Issue 4, 2004, Pages 301-306

  Menéndez Torre, Edelmiro ^a   López Carballo, María Teresa ^a   Rodríguez Erdozáin, Rosa María ^a   Forga Llenas, Lluís ^a   Goñi Iriarte, María José ^a   Barbería Layana, Juan José ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; THYROGLOBULIN;

ADULT; ARTICLE; CANCER RECURRENCE; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SCINTILLATION CAMERA; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY SCANNER;

EID: 2342590775     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072504323030960     Document Type: Article

References (19)

1. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
2. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. Clin Endocrinol Metab 86:1447-1463.
3. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfinan SG 1996 Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 156:2165-2172.
4. Holzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, Stewart AK, Hundahl SA 2000 Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer 89:192-201.
5. Schlumberger M, Baudin E 1998 Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249-252.
6. Torrens JI, Burch HB 2001 Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol Metab Clin North Am 30:429-467.
7. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FF, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD 1997 Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896.
8. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR III, Cavalieri RR, Spence CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885.
9. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625.
10. De Groot LJ, Kaplan EL, McMormick M, Strauss FH 1990 Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424.
11. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178.
12. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501.
13. Fatemi S, Nicoloff J, LoPresti J, Spencer S 2001 TSH-stimulated serum thyroglobulin in the 1-10 ng/ml range suggests a low long-term recurrence risk for papillary thyroid cancer (PTC) [Abstract 194]. Program of the 73rd Annual Meeting of the American Thyroid Association, Washington, D.C., pp. 280.
14. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT 1999 Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid 9:435-441.
15. Schlumberger M, Baudin E 1998 Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur J Endocrinol 138:249-252.
16. Wartofsky L 2002 Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. J Clin Endocrinol Metab 87:1486-1489.
17. Giovanni V, Arianna LG, Antonio C, Francesco F, Michele K, Giovanni S, Marco S, Giovanni L 2002 The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 56:247-252.
18. de Keizer B, Koppeschaar HP, Zelissen PM, Lips CJ, van Rijk PP, van Dijk A, de Klerk JM 2001 Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med 28:198-202.
19. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A 2001 Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464-1469.